CPSE:ALK B

Stock Analysis Report

Executive Summary

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally.


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has ALK-Abelló's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALK B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.6%

ALK B

2.6%

DK Pharmaceuticals

4.9%

DK Market


1 Year Return

29.2%

ALK B

-3.7%

DK Pharmaceuticals

-0.6%

DK Market

Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned -2.6% over the past year.

Return vs Market: ALK B exceeded the Danish Market which returned 0.5% over the past year.


Shareholder returns

ALK BIndustryMarket
7 Day6.6%2.6%4.9%
30 Day-23.4%-12.9%-14.4%
90 Day-13.5%-13.4%-12.9%
1 Year29.2%29.2%1.9%-3.7%2.4%-0.6%
3 Year41.3%41.3%14.3%1.3%30.0%19.0%
5 Year91.5%89.5%9.4%-9.3%24.1%8.2%

Price Volatility Vs. Market

How volatile is ALK-Abelló's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ALK-Abelló undervalued compared to its fair value and its price relative to the market?

36.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALK B (DKK1421) is trading below our estimate of fair value (DKK2242.86)

Significantly Below Fair Value: ALK B is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALK B is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ALK B is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALK B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALK B is overvalued based on its PB Ratio (4.9x) compared to the XE Pharmaceuticals industry average (2.5x).


Next Steps

Future Growth

How is ALK-Abelló forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

52.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALK B is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).

Earnings vs Market: ALK B is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALK B's is expected to become profitable in the next 3 years.

Revenue vs Market: ALK B's revenue (10.6% per year) is forecast to grow faster than the Danish market (6% per year).

High Growth Revenue: ALK B's revenue (10.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALK B's Return on Equity is forecast to be low in 3 years time (15.3%).


Next Steps

Past Performance

How has ALK-Abelló performed over the past 5 years?

-56.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALK B is currently unprofitable.

Growing Profit Margin: ALK B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALK B is unprofitable, and losses have increased over the past 5 years at a rate of -56.4% per year.

Accelerating Growth: Unable to compare ALK B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALK B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).


Return on Equity

High ROE: ALK B has a negative Return on Equity (-1.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is ALK-Abelló's financial position?


Financial Position Analysis

Short Term Liabilities: ALK B's short term assets (DKK2.2B) exceed its short term liabilities (DKK934.0M).

Long Term Liabilities: ALK B's short term assets (DKK2.2B) exceed its long term liabilities (DKK1.4B).


Debt to Equity History and Analysis

Debt Level: ALK B's debt to equity ratio (22.8%) is considered satisfactory.

Reducing Debt: ALK B's debt to equity ratio has increased from 13.8% to 22.8% over the past 5 years.


Balance Sheet

Inventory Level: ALK B has a high level of physical assets or inventory.

Debt Coverage by Assets: ALK B's debt is covered by short term assets (assets are 3.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALK B has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: ALK B has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is ALK-Abelló's current dividend yield, its reliability and sustainability?

0.25%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALK B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALK B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALK B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALK B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ALK B is not paying a notable dividend for the Danish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALK B's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Carsten Hellmann (55yo)

3.83s

Tenure

Mr. Carsten Hellmann has been the Chief Executive Officer and President at ALK-Abelló A/S since May 17, 2016. Mr. Hellmann serves as the Chief Executive Officer at Merial Inc., Merial New Zealand Limited a ...


Leadership Team

NamePositionTenureCompensationOwnership
Katja Thalund
Senior CMC Project Manager & Independent Director9.17yrsø275.00k0.00022% DKK34.0k
Carsten Hellmann
President3.83yrsno data0.019% DKK2.9m
Søren Jelert
Group CFO2.33yrsno datano data
Henrik Jacobi
Executive VP of Research & Development and Member of Board of Managementno datano data0.0055% DKK849.5k
Søren Niegel
Executive VP of Commercial Operations & Member of Management Board7.83yrsno data0.019% DKK2.9m
Per Plotnikof
Vice President of Corporate Communicationsno datano datano data
Hendrik Nolte
Senior Vice President of Research & Development - North America and International Markets3yrsno datano data
Christian Houghton
Head of Product Supply1.17yrsno datano data
Miles Guralnick
President of ALK Abelló Source Materials Incno datano datano data

3.0yrs

Average Tenure

50yo

Average Age

Experienced Management: ALK B's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Katja Thalund
Senior CMC Project Manager & Independent Director9.17yrsø275.00k0.00022% DKK34.0k
Lene Skole-Sørensen
Vice Chairman of the Board5yrsø650.00k0.011% DKK1.6m
Anders Hedegaard
Chairman of the Boardno datano datano data
Lars Holmqvist
Director5yrsø375.00kno data
Jakob Riis
Director7yrsø425.00k0.0050% DKK780.0k
Vincent Warnery
Independent Director1yrø220.00kno data
Nanna Carlson
Independent Director1yrø220.00kno data
Johan Smedsrud
Independent Director1yrø220.00kno data

5.0yrs

Average Tenure

52yo

Average Age

Experienced Board: ALK B's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ALK-Abelló A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ALK-Abelló A/S
  • Ticker: ALK B
  • Exchange: CPSE
  • Founded: 1923
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø15.446b
  • Shares outstanding: 10.90m
  • Website: https://www.alk.net

Number of Employees


Location

  • ALK-Abelló A/S
  • Boge Alle 6-8
  • Horsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALK BCPSE (OMX Nordic Exchange Copenhagen)YesB Ordinary SharesDKDKKDec 2005
0OIRLSE (London Stock Exchange)YesB Ordinary SharesGBDKKDec 2005
4AJDB (Deutsche Boerse AG)YesB Ordinary SharesDEEURDec 2005
AKBL.FOTCPK (Pink Sheets LLC)YesB Ordinary SharesUSUSDDec 2005
ALKBCBATS-CHIXE (BATS 'Chi-X Europe')YesB Ordinary SharesGBDKKDec 2005
AKAB.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDSep 2013

Biography

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 21:24
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.